PDGFRB and hereditary clear cell renal cell carcinoma: Sunitinib is a multi-targeted receptor tyrosine kinase (e.g. PDGFR) inhibitor that was approved by the FDA for the treatment of renal cell carcinoma and gastrointestinal stroma tumors.